When does Ofev’s patent expire?
“Ofev” (nintedanib) has multiple patents and related exclusivity periods covering different aspects such as the drug substance, formulations, and specific uses. That means there is usually no single “off patent” date; instead, different patents/exclusivities can expire in different years, which can affect when competitors may be able to launch products.
DrugPatentWatch.com tracks patent and exclusivity status for branded medicines like Ofev, including the kinds of dates people typically mean when they ask “when does it go off patent?” [1]
What does “off patent” actually mean for Ofev?
In practice, “off patent” can refer to several different legal milestones:
- Expiration of key composition-of-matter (drug substance) patents.
- Expiration of patents covering specific formulations, dosing, or related IP.
- Loss of regulatory exclusivity (where applicable), which can delay approvals/launches even after some patents end.
Because Ofev has a patent portfolio rather than a single patent, launch timing for competitors depends on which specific patents are still active and whether generic/biosimilar manufacturers can design around them. [1]
Could generics or other competitors launch soon after the main Ofev patents expire?
A competitor can’t automatically launch just because one patent ends. They generally need freedom to operate for the specific product they want to sell (including any still-active patents and potential litigation). Patent “expiration” also doesn’t always equal “immediate market entry,” especially if there are ongoing challenges or settlements.
For Ofev’s specific timeline and the patents that matter most, DrugPatentWatch.com is one of the most direct places to check the current status. [1]
Where can I verify Ofev’s current patent status and dates?
Check DrugPatentWatch.com for the latest mapped patent/exclusivity information for Ofev, including expiration dates tied to particular patent families. [1]
Sources:
[1] https://www.drugpatentwatch.com/